Evolution of the Average Target: TG Therapeutics, Inc.

Evolution of the Target Price: TG Therapeutics, Inc.

Changes in Analyst Recommendations: TG Therapeutics, Inc.

97c1f5d830a86c212a.0fRG55LttbUX_raywQchWqQNGvaOdu7zS2faN-vg-Hg.jrt0hM2v2MR0x9vajGhCGM4gK8HHJKWcPjeKAY2WthqggT7KzYeC23mT_w~956e4c623691c032f1a9d488cb3bfe31
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating MT
25-09-17 B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating MT
25-08-04 TG Therapeutics Q2 revenue soars, helped by BRIUMVI sales RE
25-03-04 B. Riley Raises Price Target on TG Therapeutics to $53 From $38, Keeps Buy Rating MT
25-01-07 BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating MT
24-10-29 TD Cowen Initiates TG Therapeutics at Buy With $50 Price Target MT
24-08-07 B. Riley Adjusts Target on TG Therapeutics to $34 From $29, Maintains Buy Rating MT
24-02-29 Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating MT
24-02-05 B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating MT
24-01-11 HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating MT
23-10-20 B. Riley Adjusts Price Target on TG Therapeutics to $24 From $32, Keeps Buy Rating MT
23-08-07 JPMorgan Cuts TG Therapeutics Price Target to $22 From $34, Maintains Overweight Rating MT
23-08-02 Goldman Sachs Upgrades TG Therapeutics to Neutral From Sell, Adjusts Price Target to $12 From $16 MT
23-08-02 B. Riley Lowers TG Therapeutics' PT to $32 From $42 After Lower-Than-Expected Q2 Results, Keeps Buy Rating MT
23-08-01 HC Wainwright Adjusts TG Therapeutics' Price Target to $41 From $34, Keeps Buy Rating MT
23-07-24 Goldman Sachs Adjusts TG Therapeutics' Price Target to $16 From $10, Keeps Sell Rating MT
23-05-02 Ladenburg Thalmann Raises Price Target on TG Therapeutics to $37.50 From $26, Maintains Buy Rating MT
23-05-02 B. Riley Raises TG Therapeutics' Price Target to $42 From $39 After 'Strong' Q1 Results, Keeps Buy Rating MT
23-04-14 HC Wainwright Adjusts Price Target on TG Therapeutics to $28 From $24, Reiterates Buy Rating MT
23-04-11 B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating MT
23-02-07 Cantor Fitzgerald Raises Price Target on TG Therapeutics to $24 From $18, Maintains Overweight Rating MT
23-01-24 Evercore ISI Adjusts Price Target on TG Therapeutics to $25 From $16, Maintains Outperform Rating MT
22-12-30 Evercore ISI Adjusts Price Target on TG Therapeutics to $16 From $11, Maintains Outperform Rating MT
22-12-30 Goldman Sachs Adjusts Price Target on TG Therapeutics to $6 From $4, Maintains Sell Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.2%
+6.22%
+2.73%
+3.25%
+1.86%
-1.11%
+25.51%
-1.06%
-5.15%
+21.81%
Average +6.83%
Weighted average by Cap. +5.26%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
56.04USD
Average target price
64.00USD
Spread / Average Target
+14.20%
High Price Target
83.00USD
Spread / Highest target
+48.11%
Low Price Target
20.00USD
Spread / Lowest Target
-64.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
B. Riley
TD Cowen
Goldman Sachs
HC Wainwright
JPMorgan Chase
Ladenburg Thalmann
Cantor Fitzgerald
Evercore ISI
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
56.04USD
Average target price
64.00USD
Spread / Average Target
+14.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock
  4. Consensus TG Therapeutics, Inc.